tailieunhanh - Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Everolimus, an inhibitor of mammalian target of rapamycin (mTOR), has been shown to increase the efficacy of endocrine therapies in hormone receptor (HR)-positive metastatic breast cancer. | Everolimus in hormone receptor-positive metastatic breast cancer PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN